We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
ImmunoVaccine Technologies Completes Scale-Up of VacciMax® to Commercially Relevant Scale
News

ImmunoVaccine Technologies Completes Scale-Up of VacciMax® to Commercially Relevant Scale

ImmunoVaccine Technologies Completes Scale-Up of VacciMax® to Commercially Relevant Scale
News

ImmunoVaccine Technologies Completes Scale-Up of VacciMax® to Commercially Relevant Scale

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "ImmunoVaccine Technologies Completes Scale-Up of VacciMax® to Commercially Relevant Scale"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

ImmunoVaccine Technologies Inc. (IVT) announced that it has successfully scaled-up the manufacturing process for its vaccine platform, Vaccimax®. This work validates the suitability of the platform for commercial applications in therapeutic cancer and infectious disease indications.

The manufacturing development was performed at Dalton Pharma Services, a Health Canada and GMP compliant pharmaceutical manufacturing and development company. The results show that IVT's vaccine delivery platform can be produced on a commercial scale.

IVT's product, VacciMax®, is a vaccine-enhancement platform comprised of a special emulsion of liposomes, antigens, adjuvants and oil. To prepare VacciMax® for human cancer clinical trials, IVT has been developing its platform to meet all regulatory requirements including manufacturing in a GMP setting.

The ability to scale-up, under GMP or good manufacturing practices, is mandatory for various worldwide regulatory authorities, such as the FDA. By successfully producing VacciMax® at a commercially relevant batch size, IVT plans to license its vaccine technology worldwide for the therapy and prevention of cancer and infectious diseases.

"We are pleased to collaborate with IVT and wish to congratulate the entire team on meeting such an important milestone. The successful scale-up of VacciMax® was a direct result of the Dalton and IVT teams' strong technical capabilities and project management skills," remarked Peter Pekos, President and CEO of Dalton Pharma Services.

Advertisement